SCHEMBL21621425

SCHEMBL21621425

CCOC(=O)c1cn(C2CCCCO2)nc1OC

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.38
CSNK1D P48730 1/20 0.37
NPSR1 Q6W5P4 3/20 0.36
KDM4E B2RXH2 3/20 0.36
MAPT P10636 2/20 0.36
NR2F2 P24468 2/20 0.36
MAPK1 P28482 1/20 0.36
ALDH1A1 P00352 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
S1PR2 O95136 1/20 0.36
XBP1 P17861 1/20 0.36
PPP1CA P62136 1/20 0.36
TP53 P04637 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18946294 0.87 LMNA (0.40) LMNACSNK1DNPSR1KDM4EMAPT
SCHEMBL21054420 0.86 LMNA (0.39) LMNACSNK1DNPSR1KDM4EMAPT
SCHEMBL24536577 0.85 MAOB (0.39) LMNANPSR1KDM4EMAPTMAPK1
SCHEMBL23009918 0.85 LMNA (0.39) LMNACSNK1DNPSR1KDM4EMAPT
SCHEMBL29600809 0.85 LMNA (0.38) LMNACSNK1DNPSR1KDM4EMAPT
SCHEMBL1074409 0.85 LMNA (0.38) LMNACSNK1DNPSR1KDM4EMAPT
SCHEMBL21621426 0.84 MAPK1 (0.36) MAPK1TDP1CD274ABL1
SCHEMBL25465376 0.83 LMNA (0.39) LMNACSNK1DNPSR1KDM4EMAPT
SCHEMBL14136588 0.83 CSNK1D (0.39) LMNACSNK1DNPSR1KDM4EMAPT
SCHEMBL18209791 0.82 KDM4E (0.37) LMNACSNK1DKDM4ENPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210323960-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) 2021-10-21 US disclosed
WO-2020011254-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR 正大天晴药业集团股份有限公司 2020-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323960-A1 FUSED TRI-CYCLIC COMPOUND AS PDE3/PDE4 DUAL INHIBITOR PDE3B, PDE4A, PDE3A LMNA 4377/4885CSNK1D 918/4885NPSR1 2640/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.